Business Description
Lineage Cell Therapeutics Inc
NAICS : 541713
SIC : 2836
ISIN : US09066L1052
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 11.9 | |||||
Equity-to-Asset | 0.69 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.12 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -3.86 | |||||
Beneish M-Score | -2.41 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 118.3 | |||||
3-Year EBITDA Growth Rate | 5.2 | |||||
3-Year EPS without NRI Growth Rate | 6.2 | |||||
3-Year FCF Growth Rate | -8.6 | |||||
3-Year Book Growth Rate | -16.8 | |||||
Future 3-5Y EPS without NRI Growth Rate | 5.51 | |||||
Future 3-5Y Total Revenue Growth Rate | 22.78 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 50.63 | |||||
9-Day RSI | 43.38 | |||||
14-Day RSI | 40.37 | |||||
6-1 Month Momentum % | -45.37 | |||||
12-1 Month Momentum % | -53.77 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.48 | |||||
Quick Ratio | 2.48 | |||||
Cash Ratio | 2.36 | |||||
Days Sales Outstanding | 15.86 | |||||
Days Payable | 1787.83 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.6 | |||||
Shareholder Yield % | -11.18 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 95 | |||||
Operating Margin % | -260.7 | |||||
Net Margin % | -230.66 | |||||
FCF Margin % | -264.43 | |||||
ROE % | -29.71 | |||||
ROA % | -19.52 | |||||
ROIC % | -30.02 | |||||
ROC (Joel Greenblatt) % | -482.45 | |||||
ROCE % | -26.12 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 11.45 | |||||
PB Ratio | 1.54 | |||||
Price-to-Tangible-Book | 10.76 | |||||
EV-to-EBIT | -3.94 | |||||
EV-to-Forward-EBIT | -8.52 | |||||
EV-to-EBITDA | -4.05 | |||||
EV-to-Forward-EBITDA | -8.52 | |||||
EV-to-Revenue | 10.27 | |||||
EV-to-Forward-Revenue | 6.42 | |||||
EV-to-FCF | -3.97 | |||||
Price-to-Median-PS-Value | 0.11 | |||||
Price-to-Net-Current-Asset-Value | 26.9 | |||||
Price-to-Net-Cash | 53.8 | |||||
Earnings Yield (Greenblatt) % | -25.38 | |||||
FCF Yield % | -19.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:LCTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Lineage Cell Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 8.719 | ||
EPS (TTM) ($) | -0.11 | ||
Beta | 1.45 | ||
Volatility % | 67.69 | ||
14-Day RSI | 40.37 | ||
14-Day ATR ($) | 0.054511 | ||
20-Day SMA ($) | 0.55252 | ||
12-1 Month Momentum % | -53.77 | ||
52-Week Range ($) | 0.481 - 1.61 | ||
Shares Outstanding (Mil) | 220.42 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Lineage Cell Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Lineage Cell Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Lineage Cell Therapeutics Inc Frequently Asked Questions
What is Lineage Cell Therapeutics Inc(LCTX)'s stock price today?
When is next earnings date of Lineage Cell Therapeutics Inc(LCTX)?
Does Lineage Cell Therapeutics Inc(LCTX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |